SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Tempest Therapeutics appointed John Frederick as a Class III director, effective October 13, 2026. The appointment was announced via press release on October 14, 2026, highlighting his extensive executive leadership experience in financial strategy, capital markets, and corporate governance. Frederick received an initial option award of 25,000 shares as part of his director compensation.
View raw filing on EDGAR →CDW appointed Saranga (Sam) Balaji as a director effective October 15, 2026, increasing the board from nine to ten members. Mr. Balaji, a former Global CEO of Deloitte Consulting & Advisory with three decades of technology and business leadership experience, will serve on the Audit Committee.
View raw filing on EDGAR →The board designated Trent Green, the existing CEO, to serve as interim principal financial officer on October 14, 2026. While this is technically an appointment to an additional role rather than a new hire, the disclosure centers on the principal action of taking on a new officer position (interim CFO). The appointment is material because it signals a change in the company's financial leadership structure and may indicate an interim gap in permanent CFO coverage. No compensation changes were made, and no conflicts of interest exist.
View raw filing on EDGAR →Vaxart appointed Raquel C. Bono, M.D., a retired Vice Admiral and former Director of the Defense Health Agency, to its Board of Directors effective October 16, 2026. Dr. Bono brings extensive healthcare leadership and governance experience and will chair the Stockholder Engagement Committee while serving on the Nominating and Governance Committee and Clinical and Regulatory Affairs Committee.
View raw filing on EDGAR →Samantha L. Stoddard is being appointed as Vice President, Chief Financial Officer and Treasurer of Standex International, effective December 1, 2026. The filing centers on her appointment to this principal financial officer role, with detailed disclosure of her background, compensation arrangements (base salary of $575,000, target bonus of 75%, long-term incentive awards of 175% of base salary, signing bonus of $402,500, and sign-on equity awards totaling $1,406,250), and the transition from Ademir Sarcevic who will cease serving as CFO. This is a material executive appointment affecting the company's financial leadership.
View raw filing on EDGAR →BNB Standard Corporation appointed Alex Odagiu as Chief Executive Officer and principal executive officer, effective October 19, 2026, following a comprehensive CEO search by the Board's CEO Search Committee. Odagiu's compensation package includes a base salary of $525,000, a target bonus of 75%, equity grants of 2.5% of outstanding shares, and severance terms.
View raw filing on EDGAR →Michael Lou was appointed President & Chief Executive Officer and elected to the Board effective October 19, 2026, succeeding Daniel Brown who resigned from both roles. Lou brings 25+ years of industry experience and 17 years with Chord and its predecessors.
View raw filing on EDGAR →Todd Abbott was appointed as Managing Director of Tamboran Resources Corporation effective October 19, 2026, in addition to his existing role as Chief Executive Officer, and was simultaneously appointed as a Class II director. This formalizes his leadership position at the board level as the company transitions from appraisal to development phase.
View raw filing on EDGAR →Michael Marinaro was appointed to the expanded role of President, Medtronic, effective October 14, 2026, with expanded responsibilities including oversight of Greater China operations. The appointment includes a salary increase to $1,000,000 and supplemental long-term incentive awards totaling $3.25 million.
View raw filing on EDGAR →Darren E. Guidry was appointed as Chief Executive Officer effective January 8, 2027, following the retirement of John W. Bordelon. Guidry will continue to serve on both the Company and Bank's Board of Directors in connection with his promotion to CEO.
View raw filing on EDGAR →The filing discloses both the departure of Adam Ciongoli as Chief Legal and Policy Officer and the appointment of Nicholas Trutanich as General Counsel effective December 1, 2026. While both events occur, the appointment of Trutanich to a senior legal role with specified compensation ($1.4M base, $1.4M target bonus, $2.2M annual equity target) is the principal forward-looking action. The departure is concurrent but secondary to the succession announcement. This is material as it involves a key executive leadership transition at a major public company.
View raw filing on EDGAR →ProPetro appointed Kyle Crowley as an independent director of its Board effective October 16, 2026, in connection with an increase in Board size. Crowley, who brings 30+ years of power and energy experience including 21 years at Exelon in senior roles including M&A leadership, meets NYSE independence requirements and qualifies as an audit committee financial expert, supporting the company's PROPWR growth initiative.
View raw filing on EDGAR →Will Langley was appointed as Interim Chief Financial Officer of Torrid Holdings Inc., effective October 28, 2026, with a base salary of $702,000 and a 65% target bonus, following the planned departure of Paula Dempsey effective November 12, 2026.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, Kristine Peterson and Lonnel Coats, to the Board effective October 19, 2026, increasing Board size from seven to nine members. While the disclosure also includes compensatory arrangements (equity grants and cash compensation), the principal disclosed action is the appointment of these individuals to director roles. This is material as board composition changes affect governance and investor assessment of the company.
View raw filing on EDGAR →Fernando Martins Jose Maria was appointed to serve as a member of the Board of Directors of Elventix Technology Corporation effective immediately on October 19, 2026. The disclosure centers on the appointment action itself, with background on his professional experience and confirmation of no conflicts or family relationships. Board appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →The 6-K discloses the appointment of Mr. Ou Yuyang as an executive director of Ryde Group Ltd on September 30, 2026. The filing explicitly states "the board of directors (the "Board") of Ryde Group Ltd (the "Company") appointed Mr. Ou Yuyang ("Mr. Ou") as an executive director of the Company" and provides details of his background in capital markets, private fund management, and corporate governance. This is a clear executive appointment event material to investors assessing the company's leadership.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, Ms. Carolina Lacerda and Mr. James Oates, effective September 28, 2026. While the section also mentions Mr. Dean Sparrow's resignation, the substantive focus and detail of the disclosure centers on the two new appointments, their qualifications, committee assignments, and independence determinations. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →Edward H. Kennedy was appointed to Lightwave Logic's Board of Directors effective September 23, 2026, expanding the board from six to seven members. Kennedy brings over 30 years of telecom and networking experience, including prior CEO roles at CENX and Tollgrade Communications, and current board service at Extreme Networks.
View raw filing on EDGAR →The exhibit announces the appointment of Mr. Philip Yifei Bao to Luckin Coffee's board of directors, effective September 29, 2026. This is a clear executive/governance appointment of a director. The disclosure includes his background, qualifications, and the Chairman's statement welcoming him to the Board, making this a material governance event that would affect a reasonable investor's assessment of the company's leadership composition.
View raw filing on EDGAR →The filing discloses the election of three new directors—Steven R. Stuck, Shawn Bender, and Nina Beitzel—to the Board of Directors of First United Corporation, effective September 24, 2026. The disclosure details their backgrounds, committee assignments, and compensation arrangements. This is a clear director appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →Liam Mallon, former President of ExxonMobil Upstream with 40+ years of offshore operating and capital deployment experience, was appointed as a director of TMC effective September 24, 2026, and granted 103,165 RSUs. He was also appointed Chair of the Sustainability and Innovation Committee, strengthening board oversight at a critical stage of the company's commercial deep seabed mining operations launch.
View raw filing on EDGAR →The filing discloses the election of Nick Tzitzon to Acuity's Board of Directors, effective September 24, 2026, along with his appointment to the Audit and Governance Committees. The principal disclosed action is a person taking a role as an independent director. While the Board size was also increased from nine to ten members, the core event is the appointment of a new director with significant technology and AI experience, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →Nyxoah announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. This is a material executive appointment of a named officer to a principal leadership role. Kelly brings 25+ years of MedTech leadership experience, including prior service as Chairman, President and CEO of Teleflex, and his appointment reflects the company's strategic shift to a U.S.-focused commercial organization following FDA approval of its Genio product.
View raw filing on EDGAR →Three independent directors—Christopher Bradley, Ziv Conen, and Andrew Weksler—were appointed to the board of Bluerock Acquisition Corp. II in connection with the IPO closing on September 24, 2026, with assignments to Audit and Compensation committees.
View raw filing on EDGAR →Dean Liollio was appointed as Executive Vice President and Chief Operating Officer of Plains All American Pipeline LP, effective October 2, 2026, replacing Chris Chandler who is resigning. Liollio's compensation package includes a base salary of $625,000, a 150% bonus target, and 150,000 phantom units.
View raw filing on EDGAR →Dean Liollio was appointed as Executive Vice President and Chief Operating Officer of Plains GP Holdings LP, effective October 2, 2026, replacing Chris Chandler who resigned. The appointment includes a base salary of $625,000, a 150% bonus target, and a 150,000 phantom units long-term incentive plan grant.
View raw filing on EDGAR →The exhibit is a Material Change Report (Form 51-102F3) announcing the appointment of Melanie Pump to Optimi Health's Board of Directors on September 29, 2026. While the filing also discloses Leah Hodges' resignation as Corporate Secretary and Dane Stevens' appointment to that role, the principal disclosed action is the board appointment of a new director with significant financial and governance experience. This is a material governance event affecting the composition of the board.
View raw filing on EDGAR →Kenon Holdings announces the appointment of Duncan J. Bullock to its Board of Directors as a non-executive director, effective September 29, 2026. This is a clear executive/governance appointment that would affect a reasonable investor's assessment of board composition and oversight. The disclosure explicitly names the appointee, his role, and his relevant experience in the energy sector.
View raw filing on EDGAR →The filing discloses the appointment of Hubert Crouch as Chief Executive Officer, President, and Board member of Apollo Realty Income Solutions, effective September 30, 2026. While the section also mentions the resignation of prior CEO Jess Lipsey, the principal disclosed action centers on the appointment of a new CEO with detailed background information, making exec_appointment the most salient event. This is material as it represents a change in the company's top leadership.
View raw filing on EDGAR →The filing discloses the appointment of John B. Harlow, Jr. as President and Chief Operating Officer of Larimar Therapeutics, effective September 29, 2026. While the disclosure includes compensatory details (base salary of $560,000, signing bonus, equity grants of 800,000 options and 50,000 RSUs), the principal disclosed action is the appointment of a named executive officer to a senior leadership role. This is material to investors as it represents a significant change in the Company's executive leadership structure.
View raw filing on EDGAR →The disclosure centers on the election of Charles Phillips as a director of Verizon, effective September 25, 2026. This is a clear appointment event — the principal action is a person taking a board role. While the filing mentions his participation in the standard non-employee director compensation program, the core event is the appointment itself, not a novel compensation arrangement.
View raw filing on EDGAR →Meredith S. Manning was appointed as an independent director effective October 1, 2026, with assignment as Chairperson of the Nominating and Corporate Governance Committee, bringing extensive biopharmaceutical leadership and commercial expertise.
View raw filing on EDGAR →The filing discloses both a director resignation (Jaime Cosculluela, effective September 24, 2026) and the appointment of Marc Urbach to the Board on the same date. While both events are present, the substantive disclosure centers on Urbach's appointment—his background, independence determination, compensation terms ($12,000 quarterly base fee plus $3,000 chair fee), and the executed Board of Directors Agreement. The resignation is characterized as routine (personal reasons, no disagreement). The appointment of a new independent director with specified compensation is material to investors assessing board composition and governance.
View raw filing on EDGAR →The Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026. This is a clear executive appointment to a named officer role with significant accounting and financial reporting responsibilities. The disclosure includes detailed background on his 28 years of finance and accounting experience and prior roles at major companies, consistent with standard executive appointment disclosures under Item 5.02.
View raw filing on EDGAR →Chad A. Brandt was appointed Executive Vice President - Chief Financial Officer effective September 1, 2026, representing a promotion from Senior Vice President - Chief Financial Officer, with an annual base salary of $480,000 and participation in incentive plans.
View raw filing on EDGAR →The filing discloses the Board's election of Richard J. Daly as a director effective October 14, 2026. The principal action is a person taking a role—Daly's appointment to the Board as a Class I director. While the disclosure also mentions compensatory arrangements (57,000 stock options), the core event is the appointment itself. This is material because board composition changes affect governance and investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →William H. Crampton was appointed as a director and member of the Audit and Compensation Committees on September 25, 2026, and received an equity grant of 301,205 restricted shares. The appointment represents a material change in board composition and governance structure.
View raw filing on EDGAR →The filing discloses the appointment of Bonnie Boyer as Chief Financial Officer effective October 1, 2026, succeeding Norman Roth who transitions to Advisor to the CEO. Item 5.02 explicitly covers this executive appointment, and the prose emphasizes Boyer's qualifications and her role leading the company's next growth phase. While the filing also includes compensation details (base salary $300,000, 30% target bonus, severance provisions), the principal disclosed action is the appointment itself rather than a compensation arrangement.
View raw filing on EDGAR →The filing discloses the appointment of Ross Tannenbaum as Chief Executive Officer of NextBoat Inc., effective September 28, 2026, following Board approval on September 25, 2026. While the filing also mentions the concurrent resignation of prior CEO Brian S. John, the principal disclosed action centers on Tannenbaum's appointment to the CEO role. The filing provides extensive detail on his background, compensation arrangements (including 2.5 million stock options), and employment terms, all consistent with a material executive appointment. This is a C-suite leadership change material to investors.
View raw filing on EDGAR →The filing discloses the appointment of Naveen Jain to Celularity's Board of Directors effective upon completion of the Rule 14f-1 information statement process. This is a material board appointment of a prominent entrepreneur and CEO with significant experience in technology and health sectors. The appointment was designated by investors in connection with the Company's September 2026 financing, and is accompanied by the resignation of director Diane Parks, making this a significant governance event.
View raw filing on EDGAR →Terry L. Nutt was appointed as CEO and President effective January 1, 2027, with board membership to follow. The appointment includes a detailed employment agreement with $1.2M base salary, 135% target bonus, and 700% long-term incentive compensation. Mark McFarland transitioned from CEO to Senior Advisor role as part of the succession.
View raw filing on EDGAR →Kevin Christy was elected as a director representing NRPPD on Tri-State's Board of Directors, effective September 28, 2026. This is a clear appointment of a director to the board, which is a material governance event affecting the composition of the registrant's leadership and board oversight.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Tu Jingyi as Chief Executive Officer, Chief Financial Officer, President, Treasurer, and Board member effective July 1, 2026. While the section also mentions two prior departures (Michael Woo's resignation effective November 2023 and Chi Ching Hung's resignation on July 1, 2026), the principal action disclosed is the appointment of new leadership. The detailed biography of Mr. Tu and emphasis on his qualifications further indicate that the appointment is the focal point of this disclosure.
View raw filing on EDGAR →The filing discloses the appointment of Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, to succeed Sanjay Keswani, M.D. While the disclosure also includes Dr. Keswani's departure and Dr. Roberts' compensatory arrangements (base salary of $825,000, bonus target of 60%, and equity grants totaling approximately $1.25 million), the principal action is the appointment of a named executive officer to a C-suite role. The appointment is material to investors as it affects the Company's leadership and strategic direction.
View raw filing on EDGAR →The exhibit announces two board changes effective September 3, 2026: the resignation of Glen George Wigney and the appointment of Ana Cristina Russo as an interim Board member. While both events occurred, the principal disclosed action is Russo's appointment to the Board. Her extensive background as former CFO of Patria (October 2022–April 2026) and prior senior finance roles at Philip Morris International make this a material governance change affecting board composition and expertise.
View raw filing on EDGAR →Michael J. Gayford was promoted to Chief Operating Officer effective immediately on September 28, 2026, assuming operational responsibility for the Company's North American operations. This is a material executive appointment to a C-suite officer position, representing a significant expansion of his role from Executive Vice President of Operations. The disclosure clearly centers on the appointment action itself, with detailed background on his qualifications and responsibilities.
View raw filing on EDGAR →Russell Tiejema was appointed as Executive Vice President and Chief Financial Officer of Vestis Corporation effective September 28, 2026, succeeding interim CFO Adam K. Bowen. The appointment includes a base salary of $700,000, target bonus of 100%, a sign-on equity award of $2,500,000, and annual long-term incentive plan grants of $1,750,000.
View raw filing on EDGAR →The filing discloses both the resignation of Gianluca Fuggetta as principal financial officer (effective September 30, 2026) and the appointment of Gene Mack as interim Chief Financial Officer (effective October 1, 2026). While both events occur, the principal disclosed action centers on the appointment of Mack to assume the duties of principal financial officer and principal accounting officer. The appointment of an interim CFO is material to investors as it signals a change in financial leadership and potential operational continuity concerns, particularly given the company is conducting an ongoing search for a permanent replacement.
View raw filing on EDGAR →Dipti Vachani was appointed as Chief Executive Officer and Board member of Adeia Inc., effective October 12, 2026, succeeding Paul E. Davis who resigned. Vachani brings 30 years of semiconductor industry experience and will receive a base salary of $730,000 and an $11 million equity grant, with severance protections.
View raw filing on EDGAR →Aditya J. Gandhi was appointed Vice President and Chief Accounting Officer of Graphic Packaging effective September 28, 2026. The disclosure centers on the appointment of a named executive officer to a senior financial role, with details on his background, compensation (restricted stock units valued at ~$715,000 vesting over three years and a $105,000 cash sign-on bonus), and reporting structure. This is a material executive appointment that would affect investor assessment of the company's financial leadership.
View raw filing on EDGAR →